Subscribe to Press Releases


Immunotherapies for Life

Tumor Immunotherapy through GD2-GD3 Vaccine

Neuroectoderm-derived tumors, including neuroblastoma and sarcomas, have high expression of tumor antigens GD2 and GD3. Our bivalent GD2-GD3 Vaccine was developed by scientists at MSK for the immunization of high risk neuroblastoma patients previously treated with naxitamab. The vaccine in combination with adjuvants can induce patients to produce their own anti-GD2 and anti-GD3 serum titers, with the purpose of preventing subsequent relapse.

Our GD2-GD3 Vaccine is currently in an ongoing Phase II study at MSK.